Graduate in Physical Activity and Sport Sciences, PhD in Epidemiology and Public Health and researcher in the area of Preventive Medicine and Public Health at the University of Alcalá
In the year 2023, Science magazine has chosen the development and discovery that GLP-1 medications, agonists of the glucagon-like peptide-1, can mitigate health issues associated with obesity as the most important scientific breakthrough. Similarly, Nature magazine has selected biochemist Svetlana Mojsov, a key figure in the discovery of GLP-1, as one of the top ten scientists of the year.
In Spain, both in the child and adult populations, excess weight and obesity are more prevalent among men. Additionally, lower educational levels, lower income, disability, and the presence of individuals with obesity in the household are factors associated with a higher prevalence of excess weight and obesity. These are some of the conclusions drawn from two scientific articles and two complementary reports prepared by the National Center for Epidemiology of the Carlos III Health Institute and the Spanish Agency for Food Safety and Nutrition (AESAN). The data is derived from the ENE-COVID survey, which investigated the seroprevalence of COVID-19 infection in Spain.
Obesity is a growing public health problem for the entire planet. According to the 2023 Obesity Atlas published this week by the World Obesity Federation, 51% of the world's population will be overweight or obese (more than 4 billion people) by 2035, up from 38% today. At a briefing organised by SMC Spain ahead of World Obesity Day on 4 March, two experts discussed the role that drugs can play in combating a disease whose roots are social and linked to inequality.